Published on
07:03 GMT
FDA Approves Seventh Ustekinumab Biosimilar, Steqeyma
The US Food and Drug Administration (FDA) has approved ustekinumab-stba (Steqeyma) as a biosimilar to the interleukin-12 and -23 inhibitor ustekinumab (Stelara) for the treatment of adults with active Crohn’s disease or ulcerative colitis and for both …
Source:
Medscape
-
Neutral
